ArticleCureus2026

Marked Clinical and Functional Response to Tezepelumab After Failure of Anti-Interleukin-5 (Anti-IL-5) Therapy in Severe Asthma.

Makoto Fujimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.